RAPP (Rapport Therapeutics) Ending Cash Position : $56.91 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics Ending Cash Position?

Rapport Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 was $56.91 Mil.

Rapport Therapeutics's quarterly Ending Cash Position declined from Jun. 2024 ($110.27 Mil) to Sep. 2024 ($39.42 Mil) but then increased from Sep. 2024 ($39.42 Mil) to Dec. 2024 ($56.91 Mil).

Rapport Therapeutics's annual Ending Cash Position increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($70.25 Mil) but then declined from Dec. 2023 ($70.25 Mil) to Dec. 2024 ($56.91 Mil).

Rapport Therapeutics Ending Cash Position Historical Data

The historical data trend for Rapport Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics Ending Cash Position Chart

Rapport Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Ending Cash Position

70.25

56.91

Rapport Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial				70.25	74.37	110.27	39.42	56.91

Rapport Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Rapport Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	70.254	+	-13.344
	=	56.91

Rapport Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	39.419	+	17.491
	=	56.91

Rapport Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Rapport Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapport Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

1325 Boylston Street, Suite 401, Boston, MA, USA, 02215

Website

https://www.rapportrx.com

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.